Tirzepatide Factory Supply Tirzepatide 10 mg 15mg Weight Loss Peptide 10mg 99.9% CAS: 2023788-19-2

Yang

Email:sales1@sjztongyao.com

Whatsapp：15532163527

Tirzepatide is the world’s first GLP1/GIP dual receptor agonist developed by Eli Lilly and Company. It exhibits potent glucoselowering effects and significant weight reduction, represen ting a breakthrough in the treatment of type 2 diabetes and obesity.It improves glucose control by enhancing glucosedependent insulin secretion, suppressing inappropriately elevated glucagon secretion, and delaying gastric emptying. It also reduces food intake and body weight through central effects on appetite and satiety.

Tirzepatide demonstrates a significantly greater reduction in HbA1c than semaglutide, SGLT2 inhibitors, and metformin. The 15 mg group achieves an average weight loss of 15%–22.5%, with a more pronou nced reduction in visceral fat. GIP mediates bidirectional regulation of glucagon, resulting in a lower risk of hypoglycemia during weight loss in nondiabetic patients. Tirzepatide also improves blood lipids, blood pressure, and fatty liver, and provides potential betacell protection.

1. Powerful Glucose-Lowering (For Type 2 Diabetes)
Tirzepatide is one of the most effective glucose-lowering drugs available. Its main mechanisms include:
- Dual Incretin Effect: In a glucose-dependent manner, it stimulates pancreatic β-cells to secrete insulin while inhibiting the secretion of glucagon , thereby achieving precise blood sugar regulation.
- Improved Function: It enhances pancreatic β-cell function and insulin sensitivity (IS), helping the body utilize glucose more effectively.
- Delayed Absorption: By activating GLP-1 receptors, it delays gastric emptying and slows the absorption of sugars from food, thereby stabilizing postprandial blood glucose levels.
- Efficacy Data: Clinical studies have shown that it is more effective in reducing glycated hemoglobin  than existing drugs such as dulaglutide and semaglutide. In some patients,  levels can return to normal after treatment.

2. Significant Weight Loss (For Obesity/Overweight)
This is another core effect of tirzepatide, with even greater weight loss efficacy than standalone GLP-1 drugs:
- Appetite Suppression: It crosses the blood-brain barrier and acts on the appetite center in the hypothalamus. The GIP component not only enhances the weight loss effect of GLP-1 but also effectively suppresses appetite and increases satiety.
- Metabolic Regulation: It acts on white adipose tissue, improving fat tissue function and reducing visceral fat accumulation.
- Reduced Side Effects: Activation of GIP receptors also helps alleviate common gastrointestinal side effects associated with GLP-1 drugs, such as nausea and vomiting, improving tolerability.